Analytical Data
-
Gene name
SLAMF7/CRACC/CD319
- Application
-
Alternative Names
CD319; CRACC; 19A; CS1; CD2-like receptor-activating cytotoxic cells; Membrane protein FOAP-12
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q9NQ25
-
Expression Region
Ser23~His175
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLAMF7, also known as CRACC or CD319, is an important member of the SLAM (Signaling Lymphocyte Activation Molecule) family, primarily expressed on immune cells such as natural killer (NK) cells and certain T cells. This protein plays a crucial role in modulating immune responses, influencing both activating and inhibitory signals within the immune system. Due to its involvement in tumor immunity and viral infections, SLAMF7 has garnered significant attention as a potential therapeutic target in cancer treatment, particularly for multiple myeloma where its expression is notably upregulated. Research has revealed that SLAMF7 engagement enhances NK cell cytotoxicity and cytokine production, while also promoting immune system activation. As a result, recombinant forms of SLAMF7 are being explored for their ability to serve as therapeutic agents or targets in immunotherapies, including monoclonal antibodies. Despite promising findings, a comprehensive understanding of its signaling pathways and functional roles in different immune contexts remains necessary to harness its full therapeutic potential effectively.
